

CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

1 Claim 20 (currently amended) Recombinant poxvirus
2 comprising in the viral genome at least two expression cassettes,
3 each comprising [[the]] a cowpox ATI promoter according to SEQ ID
4 NO:1, a polynucleotide sequence in which not more than 6
5 nucleotides are substituted, deleted, and/or inserted into SEQ ID
6 NO:1 and still active as an ATI promoter, or a polynucleotide
7 comprising at least 10 nucleotides including nucleotides 22 to 29
8 of SEQ ID No: 1 and still active as an ATI promoter or a derivative
9 thereof or a subsequence of the ATI promoter or the derivative
10 thereof and a coding sequence, wherein the expression of the coding
11 sequence is regulated by said promoter or said polynucleotides,
12 derivative or subsequence and wherein the derivative of the cowpox
13 ATI promoter is a sequence that has a homology of at least 60% when
14 compared to the sequence of SEQ ID.: No. 1 and/or a sequence in
15 which not more than 6 nucleotides are substituted, deleted and/or
16 inserted in the sequence of SEQ ID.: No. 1, wherein the subsequence
17 of the ATI promoter has a length of at least 10 nucleotides of the
18 sequence of SEQ ID.: No. 1 and wherein the promoter, derivative or
19 subsequence has the biological activity of being active as a
20 promoter.

1 Claim 21 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter, derivative
3 or subsequence has the biological activity of being active as a
4 Vaccinia virus late promoter.

1 Claim 22 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter is SEQ ID
3 No: 1 or a promoter, derivative or subsequence polynucleotide which
4 comprises at least 10 nucleotides including nucleotides 25 to 29 or
5 22 to 29 of SEQ ID No:1 and still active as an ATI promoter.

1 Claim 23 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoters in each
3 expression cassette, derivatives or subsequences in the recombinant
4 poxvirus are the same identical to one another.

1 Claim 24 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least two expression cassettes
3 are inserted into the same insertion site in the poxvirus genome.

1 Claim 25 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter in at least
3 one of the expression cassettes has the sequence of SEQ ID.: No. 1.

1 Claim 26 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter in at least

3 one of the expression cassettes is a derivative of the ATI promoter
4 or a subsequence of the ATI promoter or a derivative thereof has
5 the sequence of SEQ ID.: No. 1.

1 Claim 27 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein the poxvirus is selected from the
3 group consisting of orthopoxviruses and avipoxviruses.

1 Claim 28 (previously presented) Recombinant poxvirus
2 according to claim 27, wherein the orthopoxvirus is a vaccinia
3 virus and wherein the avipoxvirus is selected from the group
4 consisting of canarypoxvirus and fowlpoxvirus.

1 Claim 29 (previously presented) Recombinant poxvirus
2 according to claim 28, wherein the vaccinia virus is modified
3 vaccinia virus strain Ankara (MVA), in particular MVA-BN and MVA
4 575, deposited under numbers V00083008 and V00120707, respectively,
5 at the European Collection of Animal Cell Cultures (ECACC).

1 Claim 30 (previously presented) Recombinant poxvirus
2 according to claim 29, wherein at least one of the expression
3 cassettes is inserted in a naturally occurring deletion site of the
4 MVA genome with respect to the genome of the vaccinia virus strain
5 Copenhagen.

1 Claim 31 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least one of the expression
3 cassettes is inserted in an intergenic region of the poxvirus
4 genome.

1 Claim 32 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least one of the coding sequences
3 codes for at least one antigen, antigenic epitope, and/or a
4 therapeutic compound.

Claim 33 (canceled)

1 Claim 34 (previously presented) Vaccine or
2 pharmaceutical composition comprising a recombinant poxvirus
3 according to claim 20.

Claim 35 (canceled)

1 Claim 36 (withdrawn) Method for introducing coding
2 sequences into target cells comprising the infection of the target
3 cells with the virus according to claim 20.

1 Claim 37 (withdrawn) Method for producing a peptide,
2 protein and/or virus comprising:

3 a) infection of a host cell with the recombinant poxvirus
4 according to claim 20,

5 b) cultivation of the infected host cell under suitable
6 conditions, and
7 c) isolation and/or enrichment of the peptide and/or
8 protein and/or viruses produced by said host cell.

1 Claim 38 (withdrawn) Method for effecting an
2 immunological response in a living animal host including a human
3 comprising administering the virus according to claim 20 to the
4 animal or human to be treated.

1 Claim 39 (withdrawn) Method according to claim 38
2 comprising the administration of at least 10^2 TCID₅₀ (tissue culture
3 infectious dose) of the virus.

1 Claim 40 (withdrawn) A cell containing the virus
2 according to claim 20.

1 Claim 41 (previously presented) A method for the
2 production of a recombinant virus according to claim 20 comprising
3 the step of inserting at least two expression cassettes into the
4 genome of a poxvirus.

1 Claim 42 (withdrawn) Method for effecting an
2 immunological response in a living animal host, including a human,
3 comprising administering the composition or vaccine according to
4 claim 34 to the animal or human to be treated.